Ayman Qasrawi, MD

Dr. Qasrawi graduated from the Hashemite University College of Medicine in Jordan in 2012. Upon graduation, he received an Award of Academic Achievement and was ranked the 2nd among his class. To further develop his interests in hematology and oncology, he later worked as a transitional resident at King Hussein Cancer Center, which is the largest cancer hospital in Jordan.

In 2015, Dr. Qasrawi joined the internal medicine residency program at the University of Missouri-Kansas City. Upon graduation, he received multiple awards including the Women of Saint Luke’s Award for 2018 presented by the Saint Luke’s Foundation, Award for Most Productivity in Research and Scholarly Activity in Internal Medicine Residency and the Second Place in Residents’ Research Day.

In June 2018, Dr. Qasrawi joined the hematology and medical oncology fellowship training at the University of Kentucky where he continued to nourish his academic interests in hematology. Upon finishing his training in June 2021, he received multiple Awards for Outstanding Achievement in Hematology and Oncology In-Training Exams as well as a Letter of Achievement from the fellowship training committee for three consecutive years. Dr. Qasrawi has strong clinical and academic interests in acute leukemias and stem cell transplantation. During his training, he presented his research at multiple local and national conferences including the ASH, ASCO, ASTCT, ACG, ATS, and NCCN. He is first author or co-author of 19 peer-reviewed manuscripts and numerous abstracts. His collaborative work in hemophagocytic histiocytosis with the University of Nebraska was awarded the 2020 American Society of Hematology Abstract Achievement Award. In addition, his work in mixed phenotype leukemia was nominated for the 2020 American Journal of Hematology Young Investigator Award.

Beginning July 2020, Dr. Qasrawi joined the Division of Hematology, Bone Marrow Transplantation & Cellular Therapy at the University of Kentucky where he primarily sees patients with myeloid malignancies including acute myeloid leukemia, myelodysplastic syndromes, chronic myeloid leukemia, and myeloproliferative disorders. In addition, he performs both allogenic and autologous stem cell transplants for patients with myeloid malignancies as well as multiple myeloma and lymphomas. Dr. Qasrawi is also interested in clinical trial development for acute leukemias and other myeloid malignancies.

Dr. Qasrawi is certified by the American Board of Internal Medicine and is a member of ASH, ASCO and ASTCT societies.